Standard Multiple and Single Daily Dosing of Amikacin in Premature Infants

Authors

1 Department of Pediatrics, Shahid Akbarabadi Hospital, Iran University of Medical Sciences, Tehran, Iran

2 Department of Pediatrics, Ali Asghar Children Hospital, Iran University of Medical Sciences, Tehran, Iran

3 Pediatrics Department,Shahid Akbar abadi Hospital,Iran University of Medical sciences

Abstract

Background: Bacterial sepsis is highly prevalent among premature infants. Amikacin is an antibiotic widely recommended for the treatment of neonatal sepsis, one of the consequences of which might be nephrotoxicity. The present study aimed to compare the efficacy and nephrotoxicity of multiple daily dosing (MDD) and once-daily dosing (ODD) of amikacin in preterm infants suspected of sepsis.
Methods: This triple-blind, randomized, controlled clinical trial was conducted on 40 premature infants suspected of sepsis, who were randomly divided into two groups. In addition to ampicillin, one group was administered with the standard daily dose, and the other group received an ODD of intravenous amikacin. Maximum and minimum serum levels of amikacin and urine neutrophil gelatinase-associated lipocalin (NGAL) were measured in both groups. Data were extracted and analyzed based on the research hypothesis and literature review.
Results: No significant differences were observed between the study groups in terms of gender, gestational age, mode of delivery, birth weight, and Apgar score. After the intervention, mean plasma creatinine reduced in both groups, while the mean reduction was significantly higher in the group administered with the ODD of amikacin (P=0.0001). However, mean changes in the urine NGAL had no significant difference between the groups (P=0.635). Minimum and maximum serum levels of amikacin in the study groups indicated a more significant reduction in mean level of the infants administered with the ODD of amikacin compared to the MDD group (P=0.0001).
Conclusion: Considering the higher maximum and lower minimum levels of amikacin in the neonates receiving the daily dosage regimen, it seems that this regimen is more effective in the treatment of sepsis in preterm infants. Moreover, no significant difference was observed in the efficacy and nephrotoxicity of the daily amikacin dosing in the premature infants suspected of sepsis compared to those treated by multiple doses of amikacin. 

Keywords


1. Fanaroff AA, Fanaroff RJ, Martin RJ. Neonatalperinatal medicine: diseases of the fetus and infant. 9th ed. St. Louis: Mosby; 2011. P. 102-5.

2. Stoll BJ, Shane AL. Infections of the neonatal infant. In: Behrman RE, Kliegman RM, editors. Nelson textbook of pediatrics. 20th ed. Philadelphia: W.B. Saunders; 2016. P. 909-25.

 3. Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith DM. Individualized dosing of amikacin in neonates: a pharmacokinetic/ pharmacodynamic analysis. Eur J Clin Pharmaco. 2009; 65(7):705-13.

 4. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011; 79(1):33-45.

 5. McWilliam SJ, Antoine DJ, Sabbisetti V, Turner MA, Farragher T, Bonventre JV, et al. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS One. 2012; 7(8):e43809. 6.

6. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinaseassociated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009; 54(6):1012-24.

7. Tugay S, Bircan Z, Cağlayan C, Arisoy AE, Gökalp AS. Acute effects of gentamicin on glomerular and tubular functions in preterm neonates. Pediatr Nephrol. 2006; 21(10):1389-92.

8. Nestaas E, Bangstad HJ, Sandvik L, Wathne KO. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2005; 90(4):F294-300.

9. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997; 24(5):786-95.

 10. Stoll BJ. Infections of the neonatal infant. In: Behrman RE, Kliegman RM, editors. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Elsevier Saunders; 2011. P. 629-48.

11. Young TE, Mangum B. NEOFAX 2011: A Manual of Drugs Used in Neonatal Care. 24th ed. Montvale: Thomson Reuters; 2011. P. 4-6.

 12. Samiee-Zafarghandy S, van den Anker JN. Nephrotoxic effects of aminoglycosides on the developing kidney. J Pediatr Neonat Individ Med. 2013; 2(2):e020227.

 13. Van den Anker J, Allegaert K. Pharmacokinetics of aminoglycosides in the newborn. Curr Pharm Des. 2012; 18(21):3114-8.

 14. Jackson GG, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis. 1990; 162(2): 408-13.

15. Bleyzac N, Varnier V, Labaune JM, Corvaisier S, Maire P, Jelliffe RW, et al. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol. 2001; 57(6- 7):499-504.

 16. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987; 155(1):93-9.

 17. Treluyer JM, Merle Y, Tonnelier S, Rey E, Pons G. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. 2002; 46(5):1381-7.

18. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012; 51(2):105-17.

 19. Gonzalez LS, Spencer JP. Aminoglycosides: a practical review. Am Fam Physician. 1998; 58(8):1811-20.

 20. Barclay ML, Begg EJ, Duffull SB, Buttimore RC. Experience of once-daily aminoglycoside dosing using a target area under the concentration–time curve. Aust NZ J Med. 1995; 25(3):230-5.

21. Barza M, Ioanidis JP, Cappeleri GC, Lau J. Single or multiple daily doses of aminoglycosides: a metaanalysis. BMJ. 1996; 312(7027):338-45.

 22. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997; 24(5):786-95.

 23. Rybi-Szuminska A, Wasilewska A, Litwin M, Kulaga Z, Szuminski M. Pediatrics normative data for urine NGAL/creatinine ratio. Acta Paedatr. 2013; 102(6): e269-72.

 24. Cangemi G, Storti S, Cantinottii M, Fortunato A, Emdin M, Bruschettini M, et al. Reference values for urinary neutrophil gelatinase-associated lipocalin (NGAL) in pediatric age measured with a fully automated chemiluminescent platform. Clin Chem Lab Med. 2013; 51(5):1101-5.

25. Abdel‐Hady E, El Hamamsy M, Hedaya M, Awad H. The efficacy and toxicity of two dosing‐regimens of amikacin in neonates with sepsis. J Clin Pharm Ther. 2011; 36(1):45-52.

 26. GuadalupeVasquez-Mendoza M, Vargas-Origel A, Del Carmen Ramos-Jimenez A, Aguilar-Orozco G, Romero-Gutierrez G. Efficacy and renal toxicity of one daily dose of amikacin versus conventional dosage regime. Am J Perinatol. 2007; 24(2):141-6.

 27. Najmeddin F, Ahmadi A, Mahmoudi L, Sadeghi K, Khalili H, Ahmadvand A, et al. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients. Acta Med Iran. 2014; 52(9):703-9.

28. Kafetzis DA, Sianidou L, Vlachos E, Davros J, Baïramis T, Papandreou Y, et al. Clinical and pharmacokinetic study of a single daily dose of amikacin in pediatric patients with severe gramnegative infections. J Antimicrob Chemother. 1991; 27(Suppl C):105-12.

 29. Pacifici GM. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol. 2009; 65(4):419-27.

30. Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy. 1999; 19(11):1252-60.